OmniSeq News

Cancer-testis antigen detection by targeted RNA sequencing

Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors.  This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as...

read more

Cancer testis antigen co-expression landscape in solid tumors

Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for...

read more

Follow Us on Twitter

Some nice coverage on @OmniSeq's NYS CLEP approval of OmniSeq INSIGHT by @BfloBizFirst
@Labcorp @illumina @Covance
#PrecisionMedicine #oncology

BREAKING NEWS! OmniSeq has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program for its cancer genomic and immune profiling test called OmniSeq INSIGHT.
@illumina @Labcorp @Covance @GenomeWeb

Learn how @OmniSeq contributes to the @RoswellPark Comprehensive Cancer Center's discovery of blood-based biomarkers that predict response to immune checkpoint inhibitor therapy in this recent @NatureComms article:

Check out how @OmniSeq and @RoswellPark are leveraging comprehensive immune profiling to identify potentially actionable targets for #mmunotherapy in pancreatic cancer. Download it here:
#Pancreatic #oncology #PrecisionMedicine

.@OmniSeq is partnering with the University of Pittsburgh Medical Center to employ a gene expression assay investigating the potential for personalized immunotherapy combinations for patients with head and neck squamous cell carcinoma. | @UPMC

Load More...